CorMedix Inc. (NYSEAMERICAN:CRMD) shares saw unusually-strong trading volume on Friday . Approximately 3,587,673 shares were traded during trading, an increase of 30% from the previous session’s volume of 2,749,644 shares.The stock last traded at $1.34 and had previously closed at $1.19.
Several equities research analysts have recently issued reports on the company. Zacks Investment Research lowered CorMedix from a “hold” rating to a “sell” rating in a report on Tuesday, September 25th. HC Wainwright set a $3.00 price target on CorMedix and gave the company a “buy” rating in a report on Wednesday, August 15th.
A number of institutional investors and hedge funds have recently bought and sold shares of CRMD. EAM Investors LLC acquired a new stake in CorMedix in the 3rd quarter worth approximately $701,000. Virtu Financial LLC lifted its holdings in CorMedix by 109.7% in the 3rd quarter. Virtu Financial LLC now owns 394,051 shares of the biotechnology company’s stock worth $382,000 after purchasing an additional 206,099 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in CorMedix by 49.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,673,113 shares of the biotechnology company’s stock worth $2,589,000 after purchasing an additional 886,894 shares during the last quarter.
CorMedix Company Profile (NYSEAMERICAN:CRMD)
CorMedix, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology.
Recommended Story: Closed-End Mutual Funds
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.